z-logo
open-access-imgOpen Access
Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy
Author(s) -
Mattia Quattrocelli,
Aaron S. Zelikovich,
Isabella M. Salamone,
Julie A Fischer,
Elizabeth M. McNally
Publication year - 2021
Publication title -
journal of neuromuscular diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.366
H-Index - 23
eISSN - 2214-3602
pISSN - 2214-3599
DOI - 10.3233/jnd-200556
Subject(s) - deflazacort , glucocorticoid , duchenne muscular dystrophy , medicine , muscular dystrophy , prednisone , adverse effect , endocrinology
Glucocorticoid steroids are widely used as immunomodulatory agents in acute and chronic conditions. Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy. Despite this benefit, glucocorticoid use in Duchenne Muscular Dystrophy is also associated with significant adverse consequences including adrenal suppression, growth impairment, poor bone health and metabolic syndrome. For other forms of muscular dystrophy like the limb girdle dystrophies, glucocorticoids are not typically used. Here we review the experimental evidence supporting multiple mechanisms of glucocorticoid action in dystrophic muscle including their role in dampening inflammation and myofiber injury. We also discuss alternative dosing strategies as well as novel steroid agents that are in development and testing, with the goal to reduce adverse consequences of prolonged glucocorticoid exposure while maximizing beneficial outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here